The Meningitis Vaccine Project
2014
This case follows the vaccine development for Meningitis A, a disease that routinely caused deadly epidemics in Sub-Saharan Africa. The case explores why such a vaccine had not been developed previously and how the creation of the Meningitis Vaccine Project (MVP) - a partnership between the World Health Organization (WHO) and PATH, a non-governmental organization - enabled the vaccine to be successfully developed over 10 years by creating a novel product development partnership. Students examine why the public/private partnership was successful and how such a model could be applied to the development of other vaccines and health technologies. Additionally, the case explores the strategies applied by Marc LaForce, the MVP’s director and veteran public health advocate, to make the MVP a success. In particular, the case examines the management skills LaForce exercised during his tenure to develop a vaccine that affected African countries could afford through their own health budgets.
The Meningitis Vaccine Project - Teaching Case
Related Files:
Source:
Gordon R et al. The Meningitis Vaccine Project. Global Health Education and Learning Incubator at Harvard University 2014. https://repository.gheli.harvard.edu/repository/10691.